Jelena Bila1, Aleksandra Sretenovic2, Jelena Jelicic2, Natasa Tosic3, Irena Glumac3, Marija Dencic Fekete2, Darko Antic4, Milena Todorovic Balint4, Olivera Markovic5, Zoran Milojevic6, Milica Radojkovic7, Goran Trajkovic8, Mila Puric9, Sonja Pavlovic3, Biljana Mihaljevic4. 1. Multiple Myeloma Unit of Lymphoma Center, Clinic of Haematology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: biladr.jelena@gmail.com. 2. Multiple Myeloma Unit of Lymphoma Center, Clinic of Haematology, Clinical Center of Serbia, Belgrade, Serbia. 3. Laboratory of Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia. 4. Multiple Myeloma Unit of Lymphoma Center, Clinic of Haematology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 5. Department of Haematology, Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia. 6. Department of Haematology, Clinical Hospital Centre Zvezdara, Belgrade, Serbia. 7. Department of Haematology, Clinical Hospital Centre Dragisa Misovic, Belgrade, Serbia. 8. Faculty of Medicine, Institute for Medical Statistics and Informatics, University of Belgrade, Belgrade, Serbia. 9. Hematology Divison, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Abstract
BACKGROUND: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). PATIENTS AND METHODS: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. RESULTS: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). CONCLUSION: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
BACKGROUND: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MMpatients ineligible for autologous stem cell transplantation (ASCT). PATIENTS AND METHODS: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. RESULTS: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). CONCLUSION:CRBN expression is of prognostic value in MMpatients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
Authors: Irena Misiewicz-Krzeminska; Luis Antonio Corchete; Elizabeta A Rojas; Joaquín Martínez-López; Ramón García-Sanz; Albert Oriol; Joan Bladé; Juan-José Lahuerta; Jesús San Miguel; María-Victoria Mateos; Norma C Gutiérrez Journal: Haematologica Date: 2018-03-15 Impact factor: 9.941
Authors: Laurens E Franssen; Inger S Nijhof; Chad C Bjorklund; Hsiling Chiu; Ruud Doorn; Jeroen van Velzen; Maarten Emmelot; Berris van Kessel; Mark-David Levin; Gerard M J Bos; Annemiek Broijl; Saskia K Klein; Harry R Koene; Andries C Bloem; Aart Beeker; Laura M Faber; Ellen van der Spek; Reinier Raymakers; Pieter Sonneveld; Sonja Zweegman; Henk M Lokhorst; Anjan Thakurta; Xiaozhong Qian; Tuna Mutis; Niels W C J van de Donk Journal: Oncotarget Date: 2018-09-21
Authors: Byung-Hyun Lee; Ka-Won Kang; Min Ji Jeon; Eun Sang Yu; Dae Sik Kim; Se Ryeon Lee; Hwa Jung Sung; Yong Park; Chul Won Choi; Byung Soo Kim Journal: Front Oncol Date: 2021-07-14 Impact factor: 6.244